A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1012 participants.
Also called NCT02501161
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,012 participants
- Sponsor
- Registry
-
NCT02501161 -
2014-005639-15
-
- Main results
- Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Czechia, Hungary, India, Israel, Italy, Mexico, Norway, Poland, Russia, Slovakia, South Africa, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02501161. Randomized; no masking; primary purpose treatment. Start 2016-01-31 (actual); primary completion 2018-10-03 (actual). Results posted on 2019-11-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
- Acronym
- DUAL™ VIII
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02501161- Content hash
486b51e6dc6b15abaf07f441fe19bb1c6d3ddc36b34aa6f9b3a73739cdc81cb3